SBIR and STTR Success Story for
Reaction Biology Corp

(Information Posted/Updated on 02/24/2011)

Reaction Biology Corp
1 Great Valley Parkway
Suite 2
Malvern, PA  19355

Contact:    Matthew Oristano
Phone:      203-389-7407
Web Site:

Project Title:  Kinome Drug BioAssay Platform
Related Award(s):  R44 CA114995
Technology Developed:
The "gold standard" in kinase assays is the P33 radioisotope based assay. Using SBIR grant funding, RBC created a miniaturized version of this assay called Kinase HotSpot, which uses far less enzyme, compound, and radioactive material.

Key Words:  kinase, assay, P33, kinome, radiolabeled, radioisotope, hotspot.
Uses of Technology/Products/Service:
There are over 500 kinases enzymes in the human body that control various aspects of our metabolism. Malfunctions in kinase enzyme functioning can lead to various diseases, including cancer, autoimmune, cardiovascular, and neurological conditions. Using the Kinase HotSpot platform, researchers can economically look for chemicals that inhibit the activity of over 350 different kinases, and possibly become drugs to treat these conditions.

Benefit to Company:
RBC has successfully launched its Kinase HotSpot assay service as a contract research organization. To date, RBC has over 150 customers from around the world including large pharmas, biotechs, non-profit institutions and universities. Revenues from Kinase HotSpot are in the millions per year. RBC has developed a leading position among contract research labs offering kinase assays.

How Product Was Commercialized:
Due to the intense need for economic kinase screening resources, RBC was able to commercialize the product with Google advertising, conference attendance and email marketing. That plus word of mouth and repeat business have led to a customer list of over 150, and a multimillion dollar revenue base.

Estimated Future Annual R&D and/or Sales from this Project:   $>20 million